Financial Highlights

During the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025), the Japanese economy continued to see a gradual trend toward recovery, with personal consumption remaining firm amid persisting improvements in the employment and income environment. However, the outlook remains uncertain due to sustained high resource prices and upward pressure on prices resulting from the continued trend of the weakening yen, as well as geopolitical risks and uncertainties surrounding international conditions such as US trade policies, among others.
In the fertility treatment field, to which the Kitazato Group belongs, interest in advanced treatment technology remains high in Japan against the backdrop of declining birthrates and a trend toward later marriage, and demand for fertility treatment-related products remains strong overseas supported by expanding access to treatment and improving medical standards.
In this business environment, the Kitazato Group has continued to provide a stable supply of cryopreservation related products to medical institutions both in Japan and overseas, and also made efforts to further improve production efficiency and quality. Moreover, in overseas markets, we have continued to pursue local regulatory approvals and strengthened our distributor network, focusing on Europe, the US, China, and India. Through these initiatives, we have been strengthening our business foundation with a view toward medium- to long-term growth.
The Group's consolidated financial results for the nine months ended December 31, 2025 are as follows.

[Net sales]
The Group's net sales for the nine months ended December 31, 2025 amounted to JPY 7,934 million (up 9.3% year-on-year).
In Japan, net sales amounted to JPY 2,756 million (up 3.2% year-on-year) as the sales, centered on oocyte retrieval needles and embryo transfer catheter, remained strong.
Overseas, demand for oocyte/embryo vitrification solution and Cryodevice, primarily in Europe, remained strong.
Net sales amounted to JPY 5,177 million (up 12.9% year-on-year), driven by increased sales in the US and India, among others, despite a temporary decrease in China due to a reactionary decrease following spot sales in the previous fiscal year.
Net sales increased year-on-year across all product categories of Media, Cryodevice, Medical Device, Micro Tools, and other.

[Profit]
Gross profit amounted to JPY 5,264 million (up 7.6% year-on-year) as higher sales more than offset a slight increase in the cost of sales ratio for OEM products.
Operating profit amounted to JPY 4,248 million (up 7.0% year-on-year), reflecting strategic selling, general and administrative expenses for the future, such as increased exhibition expenses for academic conferences associated with strengthening overseas expansion and higher fees associated with obtaining regulatory approvals in various countries.
Ordinary profit amounted to JPY 4,258 million (up 6.7% year-on-year) due to an increase in operating profit and supported by non-operating income such as foreign exchange gains, despite the recording of listing expenses.
As a result, profit attributable to owners of parent amounted to JPY 2,817 million (up 7.5% year-on-year).